AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20601207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium 80 mcg
Number of subjects: 85
Study 20601207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 18049436 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training for one month
Number of subjects: 29
Study 18049436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 16215365 — intervention group
Group type: EXPERIMENTAL
Intervention: prone-CV
Number of subjects: 39
Study 16215365 — intervention group
Group type: EXPERIMENTAL
Intervention: prone-HFOV
Number of subjects: 39
Study 16215365 — intervention group
Group type: COMPARATOR
Intervention: supine-HFOV
Number of subjects: 39
Study 11867492 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant function categorization of risk
Number of subjects: 319
Study 11867492 — intervention group
Group type: COMPARATOR
Intervention: Standard self-report measure (EAT)
Number of subjects: 319
Study 11867492 — intervention group
Group type: COMPARATOR
Intervention: Clinical interview
Number of subjects: 319
Study 10674880 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 390
Study 10674880 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 390
Study 7628056 — intervention group
Group type: EXPERIMENTAL
Intervention: 160‐mg sachets
Number of subjects: 12
Study 7628056 — intervention group
Group type: COMPARATOR
Intervention: 160‐mg tablets
Number of subjects: 12
Study 7628056 — intervention group
Group type: EXPERIMENTAL
Intervention: sachets
Number of subjects: 12
Study 7628056 — intervention group
Group type: COMPARATOR
Intervention: tablets
Number of subjects: 12
Study 1958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg day‐1)
Number of subjects: 15
Study 1958434 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day‐1)
Number of subjects: 15
Study 6261948 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide
Number of subjects: 43
Study 6261948 — intervention group
Group type: COMPARATOR
Intervention: Hexamethylmelamine and cyclophosphamide
Number of subjects: 43
Study 30951521 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (20 mg, intramuscular injections every 28 days for 3 years)
Number of subjects: 100
Study 30951521 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Number of subjects: 100
Study 30951521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution, intramuscular injections every 28 days for 3 years)
Number of subjects: 100
Study 30951521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27372803 — intervention group
Group type: EXPERIMENTAL
Intervention: Food assistance intervention
Number of subjects: 904
Study 27372803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 904
Study 26537789 — intervention group
Group type: EXPERIMENTAL
Intervention: Reablement (10 weeks of multicomponent home-based rehabilitation)
Number of subjects: 61
Study 26537789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 61
Study 25171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency dissection
Number of subjects: 39
Study 25171125 — intervention group
Group type: COMPARATOR
Intervention: Knot tying technique
Number of subjects: 39
Study 22259064 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 12
Study 22259064 — intervention group
Group type: COMPARATOR
Intervention: Sleep (control)
Number of subjects: 12
Study 20122369 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 300 mg/d
Number of subjects: 802
Study 20122369 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/d
Number of subjects: 802
Study 20122369 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium 600 to 1800 mg/d
Number of subjects: 802
Study 20122369 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 802
Study 17493294 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted CBT (6 weeks)
Number of subjects: 186
Study 17493294 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-directed CBT (12 weeks)
Number of subjects: 186
Study 15759021 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and potassium supplementation
Number of subjects: 261
Study 15759021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 12000814 — intervention group
Group type: EXPERIMENTAL
Intervention: Early elective surgery
Number of subjects: 1090
Study 12000814 — intervention group
Group type: COMPARATOR
Intervention: Surveillance by ultrasonography
Number of subjects: 1090
Study 9988362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 66
Study 9988362 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 150 mg/day
Number of subjects: 66
Study 7788458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 90
Study 7788458 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional case management
Number of subjects: 90
Study 7788458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no particular services)
Number of subjects: 90
Study 2152752 — intervention group
Group type: EXPERIMENTAL
Intervention: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + surgery therapy
Number of subjects: 90
Study 2152752 — intervention group
Group type: EXPERIMENTAL
Intervention: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + radiotherapy
Number of subjects: 90
Study 2152752 — intervention group
Group type: EXPERIMENTAL
Intervention: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + chemotherapy
Number of subjects: 90
Study 2152752 — intervention group
Group type: COMPARATOR
Intervention: surgery therapy
Number of subjects: 90
Study 2152752 — intervention group
Group type: COMPARATOR
Intervention: radiotherapy
Number of subjects: 90
Study 2152752 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 90
Study 6941699 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis (cranial radiation and intrathecal chemotherapy)
Number of subjects: 24
Study 6941699 — intervention group
Group type: COMPARATOR
Intervention: Healthy siblings (control group)
Number of subjects: 24
Study 6941699 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis at a young age
Number of subjects: 24
Study 6941699 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukemia patients without central nervous system prophylaxis
Number of subjects: 24
Study 30821335 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory organizational intervention (2×2 hour workshops)
Number of subjects: 625
Study 30821335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 625
Study 30821335 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory organizational intervention
Number of subjects: 625
Study 28166788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=128) received DVD puppet shows shown for five consecutive days in school and a minimum of once in the home.
Number of subjects: 253
Study 28166788 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=125) did not receive the intervention.
Number of subjects: 253
Study 28166788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=128) at follow-up.
Number of subjects: 253
Study 25605660 — intervention group
Group type: EXPERIMENTAL
Intervention: Infancy-onset dietary intervention aiming at reducing saturated fat intake
Number of subjects: 512
Study 25605660 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 512
Study 23413981 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus Reducer implantation
Number of subjects: 124
Study 23413981 — intervention group
Group type: COMPARATOR
Intervention: Sham implantation
Number of subjects: 124
Study 17237444 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (IT)
Number of subjects: 30
Study 17237444 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals (Control)
Number of subjects: 30
Study 17237444 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients (IT)
Number of subjects: 30
Study 15111232 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel melodies
Number of subjects: 0
Study 15111232 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar melodies
Number of subjects: 0
Study 15111232 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency judgments
Number of subjects: 0
Study 10740160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 10740160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9361338 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg daily)
Number of subjects: 7
Study 8245284 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping modelling problem solving (CMPS)
Number of subjects: 50
Study 8245284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery modelling
Number of subjects: 50
Study 8245284 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study 2880767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin 350 mg
Number of subjects: 81
Study 2880767 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg
Number of subjects: 81
Study 2880767 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin and Metronidazole
Number of subjects: 81
Study 31074640 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Intrepid™ Transcatheter Mitral Valve Replacement System
Number of subjects: 0
Study 31074640 — intervention group
Group type: COMPARATOR
Intervention: Surgical mitral valve replacement
Number of subjects: 0
Study 27105466 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid + lidocaine
Number of subjects: 0
Study 27105466 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 0
Study 26461064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led medicines' monitoring using the West Wales ADR Profile for Mental Health Medicines
Number of subjects: 41
Study 23512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavioral weight loss intervention
Number of subjects: 0
Study 19819677 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (30 g/ethanol/d for 28 days)
Number of subjects: 40
Study 19819677 — intervention group
Group type: COMPARATOR
Intervention: Gin (30 g/ethanol/d for 28 days)
Number of subjects: 40
Study 19624858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb intervention group (individualised programs of weight‐bearing balance and strengthening exercises)
Number of subjects: 350
Study 19624858 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb/cognition group (exercises aimed at management and improvement of function of the affected upper limb and cognition)
Number of subjects: 350
Study 19624858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (weekly group‐based exercises and a home program for twelve months)
Number of subjects: 350
Study 16412251 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation strategy using expert opinion leaders and local opinion leaders with a toolkit and formal continuing medical education sessions.
Number of subjects: 42
Study 16412251 — intervention group
Group type: COMPARATOR
Intervention: Formal continuing medical education session led by expert opinion leader for colorectal cancer.
Number of subjects: 42
Study 14751699 — intervention group
Group type: EXPERIMENTAL
Intervention: Active corticosteroid inhaler (doubling the dose)
Number of subjects: 390
Study 14751699 — intervention group
Group type: COMPARATOR
Intervention: Placebo corticosteroid inhaler (no change in dose)
Number of subjects: 390
Study 11751734 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment (n=11)
Number of subjects: 44
Study 11751734 — intervention group
Group type: EXPERIMENTAL
Intervention: Double the ACE inhibitor dose (n=11)
Number of subjects: 44
Study 11751734 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with angiotensin II antagonist (losartan, 50 mg/d; n=11)
Number of subjects: 44
Study 11751734 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with bicycle training for 30 minutes, 3 times a week (n=11)
Number of subjects: 44
Study 11751734 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 44
Study 9296425 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 5 microg/kg
Number of subjects: 200
Study 9296425 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 200
Study 9296425 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg/kg
Number of subjects: 200
Study 9296425 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 microg/kg
Number of subjects: 200
Study 9296425 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 200
Study 8111223 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (85 mg/day)
Number of subjects: 189
Study 8111223 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (87 mg/day)
Number of subjects: 189
Study 8111223 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 189
Study 8111223 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 189
Study 3024864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade) 4 mg four times daily
Number of subjects: 41
Study 3024864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3024864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade)
Number of subjects: 41
Study 30587918 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic irbesartan 150 mg
Number of subjects: 177
Study 30587918 — intervention group
Group type: COMPARATOR
Intervention: Branded irbesartan
Number of subjects: 177
Study 27543534 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Type I Block
Number of subjects: 5
Study 27543534 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Type II Block
Number of subjects: 5
Study 27543534 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular Quadratus Lumborum Block
Number of subjects: 5
Study 23876091 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-informed condition
Number of subjects: 61
Study 23876091 — intervention group
Group type: COMPARATOR
Intervention: Camera-uninformed condition
Number of subjects: 61
Study 22779430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy (FT)
Number of subjects: 72
Study 22779430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-therapeutic anticoagulation
Number of subjects: 72
Study 22779430 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 72
Study 20507967 — intervention group
Group type: EXPERIMENTAL
Intervention: XX group (alpha-actinin-3 present)
Number of subjects: 19
Study 20507967 — intervention group
Group type: COMPARATOR
Intervention: RR group (alpha-actinin-3 deficient)
Number of subjects: 19
Study 17640422 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula+LCP
Number of subjects: 30
Study 17640422 — intervention group
Group type: COMPARATOR
Intervention: Formula
Number of subjects: 30
Study 17640422 — intervention group
Group type: COMPARATOR
Intervention: Formula (first 10 days of life)
Number of subjects: 30
Study 15920053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreas transplant alone
Number of subjects: 32
Study 15920053 — intervention group
Group type: COMPARATOR
Intervention: Nontransplanted group
Number of subjects: 32
Study 12747812 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV with standard mask connected to a BiPAP ventilatory assist device
Number of subjects: 41
Study 12747812 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 41
Study 10366795 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 10x10(6) CD34+ cells/kg
Number of subjects: 80
Study 10366795 — intervention group
Group type: COMPARATOR
Intervention: Fewer than 10x10(3) CD34+ cells/kg
Number of subjects: 80
Study 10366795 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+/CD61+ megakaryocytic cell number
Number of subjects: 80
Study 10366795 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+/CD38Eth subset
Number of subjects: 80
Study 10366795 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with platelet engraftment after day 20
Number of subjects: 80
Study 8895640 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (initial interpretation by staff radiologists)
Number of subjects: 207
Study 8895640 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography (retrospective review by dedicated magnetic resonance angiographer)
Number of subjects: 207
Study 8895640 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast venography
Number of subjects: 207
Study 1825704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime-clindamycin
Number of subjects: 38
Study 1825704 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime-metronidazole
Number of subjects: 38
Study 6241622 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (250 mg/day) for eight weeks
Number of subjects: 20
Study 6241622 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (125 mg/day) alone or combined with chlorthalidone (25 mg/day) for eight weeks
Number of subjects: 20
Study 6241622 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two weeks
Number of subjects: 20
Study 31749275 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg subcutaneous on the evening before surgery and 1.2 mg after induction of anaesthesia
Number of subjects: 278
Study 31749275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 31749275 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 278
Study 30880176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glepaglutide
Number of subjects: 18
Study 30880176 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glepaglutide
Number of subjects: 18
Study 30880176 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg glepaglutide
Number of subjects: 18
Study 27238825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral mask
Number of subjects: 27
Study 27238825 — intervention group
Group type: COMPARATOR
Intervention: Conventional cuffed face mask
Number of subjects: 27
Study 26865601 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA/MTX
Number of subjects: 351
Study 26865601 — intervention group
Group type: EXPERIMENTAL
Intervention: ABA
Number of subjects: 351
Study 26865601 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 351
Study 24557425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin + Hydrocortisone
Number of subjects: 61
Study 24557425 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin + Placebo
Number of subjects: 61
Study 22467883 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer influence and conduct problems
Number of subjects: 417
Study 22467883 — intervention group
Group type: EXPERIMENTAL
Intervention: Family dysfunction
Number of subjects: 417
Study 22467883 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection sensitivity
Number of subjects: 417
Study 19409339 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 174
Study 19409339 — intervention group
Group type: COMPARATOR
Intervention: Control group (initially untreated)
Number of subjects: 174
Study 17316115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 +/- 0.19 mg iso/day)
Number of subjects: 35
Study 17316115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI; 61.7 +/- 7.4 mg iso/day)
Number of subjects: 35
Study 17316115 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 35
Study 17316115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI)
Number of subjects: 35
Study 15249363 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling with ICG staining
Number of subjects: 40
Study 15249363 — intervention group
Group type: COMPARATOR
Intervention: ILM peeling without ICG staining
Number of subjects: 40
Study 12471323 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (N = 12)
Number of subjects: 24
Study 12471323 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 24
Study 9734752 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 5
Study 9734752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 5
Study 8034778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% copolymer/0.243% sodium fluoride dentifrice
Number of subjects: 144
Study 8034778 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (same formulation without triclosan)
Number of subjects: 144
Study 8034778 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan dentifrice
Number of subjects: 144
Study 8034778 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 144
Study 8034778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 144
Study 2566537 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 21
Study 2566537 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 21
Study 2566537 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 21
Study 2566537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30860588 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 79